These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33020336)

  • 1. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
    Rangganata E; Widia F; Rahardjo HE
    Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
    Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
    Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder.
    Esin E; Ergen A; Cankurtaran M; Yavuz BB; Halil M; Ulger Z; Yeşil Y; Kuyumcu ME; Ozcan M; Cankurtaran E; Ariogul S
    Aging Ment Health; 2015; 19(3):217-23. PubMed ID: 25555041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
    Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
    Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
    Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
    Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
    Leone Roberti Maggiore U; Salvatore S; Alessandri F; Remorgida V; Origoni M; Candiani M; Venturini PL; Ferrero S
    Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1387-408. PubMed ID: 22871042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.
    Kay GG; Ebinger U
    Int J Clin Pract; 2008 Nov; 62(11):1792-800. PubMed ID: 18699842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
    Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
    Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.
    Pagoria D; O'Connor RC; Guralnick ML
    Curr Urol Rep; 2011 Oct; 12(5):351-7. PubMed ID: 21607875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of neurocognitive dysfunction with overactive bladder medications.
    Duong V; Iwamoto A; Pennycuff J; Kudish B; Iglesia C
    Int Urogynecol J; 2021 Oct; 32(10):2693-2702. PubMed ID: 34213600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
    Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
    Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis.
    Yang N; Wu Q; Xu F; Zhang X
    J Int Med Res; 2021 Sep; 49(9):3000605211042994. PubMed ID: 34510960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overactive bladder in the elderly: a guide to pharmacological management.
    Staskin DR
    Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.
    Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
    Curr Med Res Opin; 2021 Aug; 37(8):1303-1313. PubMed ID: 33890538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.
    Kessler TM; Bachmann LM; Minder C; Löhrer D; Umbehr M; Schünemann HJ; Kessels AG
    PLoS One; 2011 Feb; 6(2):e16718. PubMed ID: 21373193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
    Matta R; Gomes T; Juurlink D; Jarvi K; Herschorn S; Nam RK
    Eur Urol Focus; 2022 Sep; 8(5):1433-1440. PubMed ID: 34742663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?
    Paquette A; Gou P; Tannenbaum C
    J Am Geriatr Soc; 2011 Jul; 59(7):1332-9. PubMed ID: 21718264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.